India's stock benchmarks rise on Eternal, financials' rally
Nifty 50 (.NSEI), opens new tab added 0.1% to 25,111.6 points, while the BSE Sensex (.BSESN), opens new tab rose 0.2% to 82,330.57 as of 10:29 a.m. IST.
Eternal (ETEA.NS), opens new tab jumped as much as 14% to a record high after the online delivery firm said margins in its quick commerce segment have likely bottomed out, indicating easing competition and a potential turnaround.
The stock lent the biggest boost to the benchmarks on the day.
The positive commentary also lifted rival Swiggy's (SWIG.NS), opens new tab shares by about 5%.
Eight of the 13 major sectors declined. However, heavyweight financials (.NIFTYFIN), opens new tab rose 0.3%, led by gains in India's top two private lenders, HDFC Bank (HDBK.NS), opens new tab and ICICI Bank (ICBK.NS), opens new tab.
ICICI Bank rose 0.8%, while HDFC Bank added 0.6%, building on its gains from Monday on better-than-expected first-quarter results.
On the other hand, Reliance Industries (RELI.NS), opens new tab lost 0.5%, extending last session's 3.2% drop, as weakness in its oil-to-chemicals and retail businesses continued to weigh.
Meanwhile, investors are awaiting updates on a potential India-U.S. trade deal ahead of U.S. President Donald Trump's August 1 deadline.
"The only uncertainty right now is on U.S. tariffs. Otherwise, things are looking good from GDP growth, monsoon and inflation perspectives," said G Chokkalingam, founder and head of research at Equinomics Research.
If there's no friction or aggressive U.S. tariffs on India, markets are set for a strong rally, Chokkalingam added.
Among other stocks, exchange operator BSE (BSEL.NS), opens new tab and brokerage Nuvama Wealth Management (NUVA.NS), opens new tab rose 1.5% each, while Angel One (ANGO.NS), opens new tab jumped 4% as markets regulator SEBI said trading curbs on U.S.-based Jane Street have been lifted.
Titan Company (TITN.NS), opens new tab gained 1% after announcing it will buy a 67% stake in Dubai-based luxury brand Damas from Qatar's Mannai Corporation (MCCS.QA), opens new tab.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
15 minutes ago
- Reuters
New coal mines fell to 10-year low in 2024, but China pipeline risks oversupply, report says
BEIJING, July 28 (Reuters) - New coal mining capacity fell to a 10-year low in 2024, but future projects especially in major producer China still risk oversupply, said a new report from U.S. think tank Global Energy Monitor on Tuesday. New mines opened globally in 2024 can dig up about 105 million tons of coal per year, down 46% from 2023 and the smallest increase in a decade, the report found. That is about 1% of the 8.9 billion tons of global capacity in 2024. Construction plans in top producers China and India slowed in 2024 from previous years, explaining why new capacity fell to a 10-year low, the report said. But the researchers said the slowdown might not continue. "The slowdown likely reflects delays in expansion approvals, the inherently lengthy nature of coal mine development phases, and a potential easing of supply-demand pressure following the pandemic-fuelled surge in capacity additions over the previous two years." In China, coal mine approvals surged in 2022 after a coal and power shortage raised energy security concerns, but then dipped again as shortages turned to oversupply. Despite the drop in 2024, the world is still planning new mines that could produce over 2 billion tons per year of coal. Of the 2.27 billion tons per year in capacity under development, 1.35 million tons are in China, more than the rest of the world combined. If these projects move forward, China could see another round of overcapacity similar to 2012-2025, the researchers said. In 2015, China had to undertake major supply side reforms to shutter excess steel and coal capacity - a period that has come into the spotlight as China's industrial sector again struggles with crushing oversupply. The GEM data spans 850 new mines, expansions and recommission projects, and China, India, Australia, and Russia make up almost 90% of the proposed developments. The 2024 slowdown in new capacity isn't enough to meet global climate targets, which call for significantly cutting instead of adding coal production, the researchers said. Limiting global warming to 1.5 degrees would require reducing coal production 75% by 2030 from 2020 levels, according to a UN estimate. One of China's proposed mines, the Changtan surface coal mine in Inner Mongolia, would be one of the world's top mines for emissions of methane, a particularly potent greenhouse gas, GEM said.
The Independent
an hour ago
- The Independent
Business news live: Reaction to FTSE 100 firms including Greggs and AstraZeneca's latest profits
Despite the EU and US agreeing a basic trade deal on Monday, the FTSE 100 and some European stocks fell on the day after a strong start. The UK index ended more than half a percent down, but remains over ten per cent in the green for the year and is only just below record highs. The next test comes with Tuesday morning earning calls, with a host of big-name firms set to deliver their latest results including Greggs, AstraZeneca and Unilever. Outside of stock markets, we can expect further reaction to the latest tariffs and trade deals as Keir Starmer seeks an exemption for steel, while the latest data on UK mortgage approvals will be coming ahead of Nationwide 's latest House Price Index on Wednesday. Rachel Reeves, meanwhile, was warned by Ray Dalio over the UK's 'debt doom loop' of rising taxes and slow growth.
Reuters
an hour ago
- Reuters
AstraZeneca beats second-quarter profit expectations, maintains outlook
July 29 (Reuters) - AstraZeneca (AZN.L), opens new tab beat second-quarter earnings expectations on Tuesday, helped by strong sales of key cancer, heart and kidney disease drugs, but maintained its full-year forecast as pricing pressures and global trade risks remain challenges. The company hopes to move on from scandals in China, after indicating that any impact from probes in its second-biggest market would be minor, and focus on growing its U.S. footprint and drug pipeline to reach $80 billion in annual revenue by 2030. AstraZeneca said last week it plans to spend $50 billion to expand manufacturing and research capabilities in the United States by 2030, the latest drugmaker to ramp up investments in the country in response to President Donald Trump's tariff threat. The Anglo-Swedish drugmaker is counting on a wave of expected launches of 20 new medicines and its U.S. expansion to reach its $80 billion annual revenue target by the end of this decade. AstraZeneca, the UK's largest listed company by market value, reported revenue growth of 11% to $14.46 billion for the three-month period ended June at constant currency rates, with core earnings of $2.17 per share. "Our strong momentum in revenue growth continued through the first half of the year and the delivery from our broad and diverse pipeline has been excellent," CEO Pascal Soriot said in a statement. Analysts were expecting $14.15 billion in revenue and $2.16 in earnings per share for the second quarter, according to a company-provided consensus.
